Phase II ALTA: Brigatinib Has Promising Activity in Crizotinib-Refractory ALK+ NSCLC

June 3-7, 2016; Chicago, Illinois
Brigatinib showed a 54% ORR with a median PFS > 1 year in patients with crizotinib-refractory ALK+ NSCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.32 MB
Released: June 13, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Expert faculty share patient case examples from clinical practice that highlight the importance of biomarker testing for NSCLC, from Clinical Care Options (CCO)

Charles W. Flexner, MD Released: September 23, 2022

Phase III CodeBreaK 200 study of sotorasib vs docetaxel in previously treated KRAS G12C-mutated advanced non-small-cell lung cancer, presented at ESMO 2022 as reported by Clinical Care Options (CCO)

Released: September 22, 2022

Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC

Zofia Piotrowska, MD, MHS Karen L. Reckamp, MD, MS Released: September 21, 2022

Downloadable slideset on optimal management of EGFR+ NSCLC, including expert insights on promising investigational agents and combination therapy, from Clinical Care Options (CCO)

Edward B. Garon, MD, MS Helena A. Yu, MD Released: September 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings